Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brodalumab: A new way to inhibit IL ‐17 in psoriasis
Paola Facheris, Mario Valenti, Giulia Pavia, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Inflammation and Psoriasis: A Comprehensive Review
Alessandra-Mădălina Man, Meda Sandra Orăsan, Oana-Alina Hoteiuc, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16095-16095
Open Access | Times Cited: 36
Structure and function of therapeutic antibodies approved by the US FDA in 2023
William R. Strohl
Antibody Therapeutics (2024) Vol. 7, Iss. 2, pp. 132-156
Open Access | Times Cited: 8
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 10, pp. 2309-2324
Open Access | Times Cited: 32
Anti‐IL17 and anti‐IL23 biologic drugs for scalp psoriasis: A single‐center retrospective comparative study
Alessandra Narcisi, Mario Valenti, Andrea Cortese, et al.
Dermatologic Therapy (2021) Vol. 35, Iss. 2
Open Access | Times Cited: 29
Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors
Victoria Fang, Radhika Gupta, Robert G. Micheletti
Dermatologic Clinics (2025) Vol. 43, Iss. 2, pp. 231-245
Closed Access
Topical Therapy in Psoriasis: Clinical Benefits, Advances in Novel Drug Delivery Strategies, and Gene Therapy Regimen
Ying Zhu, Yong Zhou, Xiao-Nan Ma, et al.
Pharmaceutics (2025) Vol. 17, Iss. 3, pp. 283-283
Open Access
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study
Amera Elzubeir, Juliet High, Matthew Hammond, et al.
BMJ Open Gastroenterology (2025) Vol. 12, Iss. 1, pp. e001596-e001596
Open Access
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population
Mario Valenti, Giulia Pavia, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 3, pp. 1638-1642
Closed Access | Times Cited: 24
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Marco Galluzzo, Giacomo Caldarola, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1299-1310
Open Access | Times Cited: 24
Clinical response to brodalumab in a patient affected by refractory SAPHO syndrome
Emilio D'Ignazio, Emanuele Trovato, Luca Cantarini, et al.
Clinical and Experimental Rheumatology (2024)
Open Access | Times Cited: 2
Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
Cathrine Dawn Büttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Drugs in R&D (2023) Vol. 23, Iss. 2, pp. 155-163
Open Access | Times Cited: 6
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis
Congjun Jiang, Yu Du, X J Liu, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 1, pp. 28-36
Closed Access | Times Cited: 6
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
Yuqian Wang, Sheng Li, Juan Bai, et al.
Therapeutic Advances in Chronic Disease (2023) Vol. 14
Open Access | Times Cited: 5
The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors
Anna Davydova, Yu. D. Kurochkina, Veronika E. Goncharova, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1328-1328
Open Access | Times Cited: 5
Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review
Maria Vittoria Cannizzaro, Giulia Coscarella, Andrea Chiricozzi
Dermatology Practical & Conceptual (2023), pp. e2023245-e2023245
Open Access | Times Cited: 4
Biological therapy for psoriatic arthritis: current state and future perspectives
Dominika Boboryko, Joanna Olejnik-Wojciechowska, Magdalena Baranowska, et al.
Rheumatology International (2024)
Closed Access | Times Cited: 1
Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis
Dengqin He, Gang Li, Jia‐Qiang Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20353-20371
Closed Access | Times Cited: 1
Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )
M Tichý, Martina Kojanová, Barbora Velacková, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 10
Closed Access | Times Cited: 7
Real world experience of brodalumab treatment in patients with moderate‐to‐severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study
Dimitrios Rigopoulos, Charalampos Angelakopoulos, Zoé Apalla, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 12
Open Access | Times Cited: 6
Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment
Ш. Ф. Эрдес
Modern Rheumatology Journal (2021) Vol. 15, Iss. 2, pp. 94-105
Open Access | Times Cited: 8
Targeting IL-17A signaling in suicidality, promise or the long arm of coincidence? Evidence in psychiatric populations revisited
Carmen Schiweck, Mareike Aichholzer, Andreas Reif, et al.
Journal of Affective Disorders Reports (2022) Vol. 11, pp. 100454-100454
Open Access | Times Cited: 5
Apremilast for the treatment of palmo‐plantar non‐pustular psoriasis: A real‐life single‐center retrospective study
Giulia Pavia, Luigi Gargiulo, Andrea Cortese, et al.
Dermatologic Therapy (2021) Vol. 35, Iss. 2
Open Access | Times Cited: 7
Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A VHH Domain
Olga Kostareva, Arina Svoeglazova, Ilya Kolyadenko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14904-14904
Open Access | Times Cited: 4
Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris
Yong Chen, Mei Yi, Xiaoyan Pang, et al.
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 1, pp. 113-120
Open Access
Update on IL-17 Inhibitors for Psoriasis
Rhea Singh, Esther A. Balogh, Steven R. Feldman
Current Dermatology Reports (2020) Vol. 9, Iss. 4, pp. 339-352
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top